Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neurol Acetylcholine Receptor Subunit Alpha 7 (CHR7) - Overview
Neurol Acetylcholine Receptor Subunit Alpha 7 (CHR7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Neurol Acetylcholine Receptor Subunit Alpha 7 (CHR7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neurol Acetylcholine Receptor Subunit Alpha 7 (CHR7) - Companies Involved in Therapeutics Development
180 Life Corp
AlphaCognition Inc
AstraZeneca Plc
Bionomics Ltd
Bristol-Myers Squibb Co
DanPET AB
Epigen Biosciences Inc
Lupin Ltd
Merck & Co Inc
Neuro Bio Ltd
SK Biopharmaceuticals Co Ltd
Vanda Pharmaceuticals Inc
Neurol Acetylcholine Receptor Subunit Alpha 7 (CHR7) - Drug Profiles
ALPHA-1062 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVL-3288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVL-8168 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-0328 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-910731 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-375 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPGN-1137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LL-00066471 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NBP-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NS-12877 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKL-20540 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize CHR7 for Ulcerative Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize CHR7 for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize NMDA Receptor and CHR7 for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VQW-765 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neurol Acetylcholine Receptor Subunit Alpha 7 (CHR7) - Dormant Products
Neurol Acetylcholine Receptor Subunit Alpha 7 (CHR7) - Discontinued Products
Neurol Acetylcholine Receptor Subunit Alpha 7 (CHR7) - Product Development Milestones
Featured News & Press Releases
Nov 01, 2021: Bionomics Receives FDA clearance of IND for evaluation of BNC210 in a phase 2 social anxiety disorder PREVAIL study
Nov 01, 2021: Bionomics gets FDA approval for trial of social anxiety disorder treatment
Sep 20, 2021: Bionomics prepares BNC210 for start of phase 2 acute treatment of social anxiety disorder trial
Sep 09, 2021: Alpha Cognition to Webcast Live on ALPHA-1062 at Life Sciences Investor Forum September 16th
Sep 07, 2021: Alpha Cognition announces the acceptance of its US FDA investigatiol new drug application (IND) for lead candidate, ALPHA-1062 for mild to moderate Alzheimer’s Disease
Jul 08, 2021: Novamind selected as research site for Bionomics’ PTSD clinical trial
Jul 06, 2021: Bionomics initiates phase 2b ATTUNE study of BNC210 in PTSD
May 10, 2021: Bionomics expanding BNC210 for acute treatment of social anxiety disorder in addition to phase 2b trial for post traumatic stress disorder
Apr 30, 2021: Agilex Biolabs congratulates Bionomics on BNC210 PK results
Apr 27, 2021: Alpha Cognition announces Ms. Colleen Johns as SVP, product development further strengthening the ALPHA-1062 drug commercialization team
Apr 12, 2021: Alpha Cognition announces Mr. Michael McFadden as chief executive officer and realignment of leadership team for next stage of alpha-1062 drug development
Feb 22, 2021: Positive BNC210 7-Day dosing pharmacokinetic study exceeds blood exposure projected for phase 2b PTSD trial
Jan 18, 2021: Publication of positive BNC210 phase 2a data in generalised anxiety disorder patients
Jan 07, 2021: Bionomics presenting at virtual H.C. Wainwright Bioconnect 2021 conference
Jan 04, 2021: Bionomics initiates 7-day dosing pharmacokinetic study of BNC210 tablet formulation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by 180 Life Corp, 2021
Pipeline by AlphaCognition Inc, 2021
Pipeline by AstraZeneca Plc, 2021
Pipeline by Bionomics Ltd, 2021
Pipeline by Bristol-Myers Squibb Co, 2021
Pipeline by DanPET AB, 2021
Pipeline by Epigen Biosciences Inc, 2021
Pipeline by Lupin Ltd, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by Neuro Bio Ltd, 2021
Pipeline by SK Biopharmaceuticals Co Ltd, 2021
Pipeline by Vanda Pharmaceuticals Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Discontinued Products, 2021